133P - Identification of an epigenetic biomarker predicting the response to therapy with APG101 in glioblastoma

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Clinical research
Central Nervous System Malignancies
Translational Research
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter Meinolf Thiemann
Citation Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363
Authors M. Thiemann1, C. Gieffers1, C. Kunz2, J. Sykora1, C. Merz1, H. Fricke2, B. Wiestler3, W. Wick4
  • 1Protein Analytics, Apogenix AG, 69120 - Heidelberg/DE
  • 2Clinical Development, Apogenix AG, 69120 - Heidelberg/DE
  • 3Abteilung Für Neuroradiologie, Rechts der Isar Hospital,TUM, München/DE
  • 4Abteilung Für Neuroonkologie, University Hospital Heidelberg, Heidelberg/DE



APG101, a fully human fusion protein consisting of the extracellular domain of CD95 and the Fc-domain of an IgG, has been developed by Apogenix. It was confirmed as a potent inhibitor of CD95L induced invasion of glioblastoma cells in vitro. In a randomized phase 2 study in glioblastoma patients with 1st or 2nd relapse the combined therapy of APG101 plus radiotherapy (RT) was found to be superior to RT alone in a clinically relevant order of magnitude in all efficacy endpoints (i.e. PFS-6, PFS and OS). At the same time APG101 exhibited an excellent safety profile and was well tolerated. The presented data summarizes the identification of a predictive biomarker.


To identify potential biomarkers we used available tissue sections originating from archived primary tumor of the study patients and analyzed them for the expression of CD95L as well as for the DNA methylation status.


A genome-wide assessment of DNA methylation identified a single CpG-site (CpG2) upstream of the CD95L-promotor that showed differential methylation between APG101 responders (PFS > 5 months) and non-responders (PFS 


The level of CpG2 methylation in the CD95L promoter in the patients' glioblastoma tissue is a prognostic biomarker predicting response to therapy with APG101. Apogenix currently develops a qPCR-based assay to quantify CpG2 methylation. This assay is intended as companion diagnostic to identify patients that may respond best to APG101 treatment.

Clinical trial identification

EudraCT-Number: 2009-013421-42

Legal entity responsible for the study

Apogenix AG


Apogenix AG


M. Thiemann, C. Gieffers, C. Kunz, J. Sykora, C. Merz, H. Fricke: Employee of Apogenix AG. W. Wick: Commercial research grant from Boehringer Ingelheim and Roche; speaker's bureau honoraria from Prime Oncology; and is a consultant/advisory board member for Eli Lilly and Co. and Roche. All other authors have declared no conflicts of interest.